Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma.

Hepato-gastroenterology Pub Date : 2015-01-01

San Xiong Huang, Yu Lian Wu, Cheng Wu Tang, Wen Ming Feng, Yong Qiang Xu, Ying Bao, Yin Yuan Zheng

{"title":"Prophylactic hepatic artery infusion chemotherapy improved survival after curative resection in patients with hepatocellular carcinoma.","authors":"San Xiong Huang, Yu Lian Wu, Cheng Wu Tang, Wen Ming Feng, Yong Qiang Xu, Ying Bao, Yin Yuan Zheng","doi":"","DOIUrl":null,"url":null,"abstract":"Background/aims: To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival probability after curative resection in patients with hepatocellular carcinoma (HCC).Methodology: 85 patients with HCC were randomly assigned to HAIC group (42 cases) and control group (43 patients), all the database of two groups had no significant difference. Patients in HAIC groups underwent hepatic artery infusion chemotherapy (5-FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1 and Gemcitabine 1000 mg/m2 on day 1 and 8) starting 3 weeks after operation with intervals of 4 weeks. All patients were followed up for 3 years and intrahepatic recurrence-free survival, disease-free survival rate and overall survival rate were recorded.Results: Intrahepatic recurrence rate of HAIC group and the control group was respectively 19.05% and 39.53%, P < 0.05. Disease-free survival rate was respectively 57.14% and 44.19%, P < 0.05. Overall survival rate was 66.67% and 46.51%, P < 0.05. All patients in HAIC group tolerated the therapy. No adverse effect above grade 3 was reported in HAIC group.Conclusion: HAIC effectively and safely prevents intrahepatic recurrence and improves the prognosis of patients with HCC after curative resection.","PeriodicalId":12985,"journal":{"name":"Hepato-gastroenterology","volume":"62 137","pages":"122-5"},"PeriodicalIF":0.0000,"publicationDate":"2015-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepato-gastroenterology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aims: To explore the effect of prophylactic hepatic artery infusion chemotherapy (HAIC) on survival probability after curative resection in patients with hepatocellular carcinoma (HCC).

Methodology: 85 patients with HCC were randomly assigned to HAIC group (42 cases) and control group (43 patients), all the database of two groups had no significant difference. Patients in HAIC groups underwent hepatic artery infusion chemotherapy (5-FU 1000 mg/m2 on day 1, Oxaliplatin 85 mg/m2 on day 1 and Gemcitabine 1000 mg/m2 on day 1 and 8) starting 3 weeks after operation with intervals of 4 weeks. All patients were followed up for 3 years and intrahepatic recurrence-free survival, disease-free survival rate and overall survival rate were recorded.

Results: Intrahepatic recurrence rate of HAIC group and the control group was respectively 19.05% and 39.53%, P < 0.05. Disease-free survival rate was respectively 57.14% and 44.19%, P < 0.05. Overall survival rate was 66.67% and 46.51%, P < 0.05. All patients in HAIC group tolerated the therapy. No adverse effect above grade 3 was reported in HAIC group.

Conclusion: HAIC effectively and safely prevents intrahepatic recurrence and improves the prognosis of patients with HCC after curative resection.

微信好友朋友圈 QQ好友复制链接

本刊更多论文

预防性肝动脉输注化疗可提高肝癌根治性切除术后患者的生存率。

背景/目的:探讨预防性肝动脉灌注化疗(HAIC)对肝细胞癌(HCC)根治性切除术后生存率的影响。方法:85例HCC患者随机分为HAIC组(42例)和对照组(43例)，两组数据均无统计学差异。HAIC组患者术后3周开始肝动脉输注化疗(5-FU 1000 mg/m2，第1天，奥沙利铂85 mg/m2，吉西他滨1000 mg/m2，第1天和第8天)，间隔4周。所有患者随访3年，记录肝内无复发生存率、无病生存率及总生存率。结果:HAIC组和对照组的肝内复发率分别为19.05%和39.53%，P < 0.05。无病生存率分别为57.14%和44.19%，P < 0.05。总生存率分别为66.67%和46.51%，P < 0.05。HAIC组患者均能耐受。HAIC组无3级以上不良反应。结论:HAIC可有效、安全地预防肝内复发，改善肝细胞癌根治切除后的预后。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊